ZYME
Zymeworks Inc.
A Vancouver-based biopharmaceutical company that engineers antibody-based cancer therapies. Its Azymetric platform builds bispecific antibodies that can latch onto two targets at once, while its ZymeLink technology attaches chemotherapy drugs to antibodies to deliver them straight to tumors. Founded in 2003, the company's lead drug, zanidatamab, targets HER2-positive cancers.
CUSIP: 98985W102HealthcareCA1 holder
Total Value
$28.36M
Total Shares
976.7K
Net Share Change
0
Activity
No changes
Investor
Value
Shares
Weight
Change
